Aurobindo Pharma commissions 4 manufacturing plants for PenicillinG, other products

Hyderabad Aurobindo Pharma Limited has commissioned four state-of-the-art manufacturing facilities for PenicillinG, 6-Amino Penicillanic Acid (6-APA), Injectable products and Granulation, through its wholly owned subsidiaries- Lyfius Pharma, Qule Pharma, Eugia Steriles, Auroactive Pharma.

Whereas the injectable plant has an annual production capacity of 285 millions of Vials/Ampoules and the Granulated products plant has 13,200 tonne annually.

Please refer to the table below for the full details –

"The business of the respective entities has commenced by undertaking commercial production of the products. Based on the purchase orders received, the respective companies have made commercial sale to its customers," the Company stated in a BSE filing.

The business’ revenues and profitability of the respective entities are expected to grow over a period of time.

Aurobindo Pharma Limited is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and commercializes a wide range of generic pharmaceuticals, branded specialty pharmaceuticals and active pharmaceutical ingredients globally in over 150 countries. The company has 25 manufacturing and packaging facilities that are approved by leading regulatory agencies including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, Brazil ANVISA. The company’s product portfolio is spread over 7 major therapeutic/product areas encompassing CNS, AntiRetroviral, CVS, Antibiotics, Gastroenterological, Anti-Diabetics and Anti-Allergic, supported by a strong R&D set-up.

Read also: Aurobindo Pharma bags USFDA nod for Mometasone Furoate Monohydrate Nasal Spray